Healthpeak Properties, Inc (DOC) 2026 Q3 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good morning and welcome to the Healthpeak Properties Inc., third quarter 2026 conference call. (Operator Instructions) Please note this event is being recorded.

    早安,歡迎參加 Healthpeak Properties Inc. 2026 年第三季財報電話會議。(接線員指示) 請注意,本活動將被錄音。

  • I would now like to turn the conference over to Andrew Johns, Senior Vice President, Investor Relations. Please, go ahead.

    現在我想把會議交給投資人關係資深副總裁 Andrew Johns。請開始。

  • Andrew Johns - Senior Vice President - Investor Relations

    Andrew Johns - Senior Vice President - Investor Relations

  • Welcome. As a reminder, certain statements made in this call may be deemed forward-looking statements in the meaning of the Private Securities Litigation Reform Act. Although Healthpeak [influence] any forward-looking statements are based on reasonable assumptions, the company can give no assurances that its projected results would be obtained, and we do not undertake a duty to update any forward-looking statements.

    歡迎各位。提醒大家,本次電話會議中的某些陳述可能構成《私人證券訴訟改革法》所定義的前瞻性陳述。儘管 Healthpeak 的任何前瞻性陳述係基於合理假設,公司仍無法保證其預測結果一定能達成,且我們不承擔更新任何前瞻性陳述之義務。

  • Factors that could cause actual results to differ materially from those in the forward-looking statements are detailed in the filings with the SEC. We refer to certain non-GAAP financial measures during this call, which are reconciled to the most directly comparable GAAP measures and the exhibit to the 8-K refers to the SEC yesterday in accordance with Reg G.

    可能導致實際結果與前瞻性陳述存在重大差異的因素,已在向 SEC 提交的文件中詳述。本次電話會議中我們將提及若干非 GAAP 財務衡量指標,並已與最直接可比的 GAAP 指標進行調節;此外,我們昨日依據 Reg G 向 SEC 提交之 8-K 附件中亦有相關說明。

  • I'll now turn the call over to our President, Chief Executive Officer, Scott Brinker.

    現在我把電話會議交給我們的總裁兼執行長 Scott Brinker。

  • Scott Brinker - President, Chief Executive Officer, Director

    Scott Brinker - President, Chief Executive Officer, Director

  • Thanks, AJ, and welcome to our 3Q earnings call. I want to congratulate the team here on a very strong quarter operationally, which allowed us to increase earnings guidance for the third time this year and by a total of $0.05 per share at the midpoint.

    謝謝 AJ,歡迎參加我們第三季財報電話會議。我想祝賀團隊在營運面交出非常強勁的一季,讓我們今年第三度上調盈餘指引,且以中位數計算,全年合計上調每股 0.05 美元。

  • The guidance raises this year were primarily driven by operations across the portfolio and the flow-through impact of Janus Living. In outpatient medical, the strong fundamentals we spoke to with the merger three years ago continue to be validated.

    今年的指引上調主要由投資組合各項營運表現,以及 Janus Living 的流入效應所帶動。在門診醫療方面,我們三年前在合併時所談到的強勁基本面,持續獲得驗證。

  • Cost pressures are making outpatient delivery a strategic mandate for health systems across the country, and we play a vital role helping them address that mandate. The agent population is driving record demand and new supplies at historical lows. Against that favorable backdrop, we created the leading platform and portfolio in the outpatient sector with the merger.

    成本壓力使得門診交付成為全國各地醫療體系的策略性必須,我們在協助他們落實該策略上扮演關鍵角色。人口結構正推動創紀錄的需求,而新增供給則處於歷史低位。在這樣有利的背景下,我們透過合併打造了門診領域領先的平台與投資組合。

  • Third quarter results included positive net absorption, strong retention and re-leasing spreads and modest TIs and commissions. These are the metrics that drive cash flow and value creation. We don't focus on same-store because ignore is equally important items like CapEx and moving properties in and out of the pool.

    第三季結果包括正向的淨吸納、強勁的續租率與再出租租金價差,以及溫和的租戶裝修(TI)與佣金。這些都是推動現金流與價值創造的指標。我們不著重於同店(same-store),因為那會忽略同樣重要的項目,例如資本支出(CapEx)以及資產進出同店池的影響。

  • Our outpatient business is stronger than ever, and we expect internal growth to accelerate in 2027 given our recent lease executions and pipeline. We're also happy to have closed nearly $2 billion of fully stabilized outpatient sales, recaps and loan repayments earlier this year at a blended 6% cap rate. More than half of that amount was joint venture recaps with blue chip LPs who chose to partner with Healthpeak given our platform.

    我們的門診業務比以往更強勁,鑑於近期的租約簽署與儲備案源,我們預期 2027 年內生成長將加速。我們也很高興今年稍早已完成近 20 億美元、完全穩定的門診資產出售、資本重整(recaps)與貸款償還,合併資本化率約 6%。其中超過一半為與一流有限合夥人(LP)的合資資本重整,這些藍籌 LP 因看重我們的平台而選擇與 Healthpeak 合作。

  • Moving to our life science business. Earlier this year, we shared our expectation of growing total occupancy by 100 basis points in 2026. That was not a consensus view at the time. But we saw early signs of an improving environment, and we were confident we capture market share.

    接著談我們的生命科學業務。今年稍早,我們分享了對 2026 年總入住率提升 100 個基點的預期。當時這並非市場共識。但我們看到環境改善的早期跡象,並且有信心能夠取得市占。

  • Year-to-date, we've outperformed our own expectations. Total occupancy increased 130 basis points last quarter and by 270 basis points year-to-date, not sure anyone else in this sector could make that same claim.

    截至目前,我們的表現超出自身預期。上季總入住率提升 130 個基點,年初至今提升 270 個基點,我不確定這個產業還有誰能做出同樣的成績。

  • And why this success? We made strategic new hires. We own really good real estate. We have liquidity and credibility, and we can move quickly, given our buildings are unencumbered by third-party debt. All of those factors will continue to drive leasing outperformance.

    那麼,成功原因是什麼?我們進行了策略性的新聘用。我們擁有非常優質的不動產。我們具備流動性與可信度,而且由於我們的建物未受第三方負債所束縛,我們能快速行動。所有這些因素都將持續推動我們在租賃上的超額表現。

  • Life science job growth turned positive in 3Q, which is consistent with the growing demand that we see in our pipeline. On the supply side, we continue to see certain life science buildings go to alternative uses, which is soaking up some of the vacancy.

    生命科學就業成長在第三季轉為正值,這與我們在案源管線中看到的需求增長一致。在供給端,我們持續看到部分生命科學建物轉作其他用途,這正在吸收部分空置。

  • The robust infrastructure of the lab building is attractive to AI adjacent users, including robotics because of power, floor loads and ceiling heights. We're seeing a lot of that type of demand in the marketplace. The net effect is that supply and demand are starting to move in our favor, albeit at different rates depending on the submarket. For example, we're now fully leased in Torrey Pines versus 65% leased in that submarket just six months ago.

    實驗室建物強健的基礎設施對 AI 周邊使用者很有吸引力,包括機器人領域,原因在於電力、樓板載重與天花板高度。我們在市場上看到大量此類需求。整體效果是供需開始朝對我們有利的方向移動,儘管不同次市場的速度不一。例如,我們在 Torrey Pines 現在已全數出租,而就在六個月前該次市場的出租率仍為 65%。

  • Strong occupancy will, of course, allow us to drive better economics on future leases. We continue to make good progress at the Gateway campus we acquired earlier this year with 125,000 square feet of leases signed so far in the fourth quarter alone, plus 100,000 square feet undersigned LOI or in active discussions.

    強勁的入住率當然將使我們能在未來租約上取得更佳的經濟條件。我們在今年稍早收購的 Gateway 園區持續取得良好進展,僅第四季迄今就已簽下 125,000 平方英尺的租約,另有 100,000 平方英尺已簽署 LOI 或正積極洽談中。

  • The three acquisitions announced yesterday are building surrounded by existing Healthpeak real estate and add to our competitive advantage in core submarkets. It's a great time to be a buyer because most life science GPs, LPs and lenders are upside down.

    昨日宣布的三項收購,皆為被既有 Healthpeak 不動產所環繞的建物,進一步強化我們在核心次市場的競爭優勢。現在是很好的買方時點,因為多數生命科學領域的普通合夥人(GP)、有限合夥人(LP)與放款機構都處於資產價值低於成本的狀態。

  • Capital availability in this sector has gone from overly abundant to severely constrained. As a result, we can now buy core assets at a basis with both downside protection and significant upside. Current occupancy across the acquisitions is 41% with a 5% in-place yield going to 9% to 10% at stabilization. And these are not passive investments.

    本產業的資本可得性已從過度充裕轉為嚴重受限。因此,我們現在能以兼具下檔保護與顯著上檔空間的成本基礎買入核心資產。這些收購標的目前整體入住率為 41%,現有收益率(in-place yield)為 5%,在穩定後可提升至 9% 至 10%。而且這些並非被動式投資。

  • We're bringing our relationships and expertise to the table, and we already have strong leasing activity on 70% of the acquired vacancy. When we acquire quality real estate in our core submarkets, there's a network effect that increases the value of our entire local footprint as we become the easy button for tenants and brokers.

    我們將自身的人脈關係與專業帶到案子中,而且在已收購空置面積的 70% 上,我們已看到強勁的租賃活動。當我們在核心次市場收購優質不動產時,會產生網路效應,提升我們整體在地版圖的價值,因為我們會成為租戶與仲介最容易選擇的對象。

  • More broadly, we entered the sector downturn in 2022 as the number three player in life science real estate. We're entering the recovery as the only company growing its footprint and adding talent. More work to do, but we're on a trajectory to become the leading portfolio and platform in the life science real estate sector.

    更宏觀地看,我們在 2022 年進入本產業下行週期時,是生命科學不動產的第三大業者。而在復甦階段,我們是唯一一家持續擴大版圖並增聘人才的公司。仍有更多工作要做,但我們正走在成為生命科學不動產領域領先投資組合與平台的軌道上。

  • In senior housing, the lifestyle and value of our communities is driving higher occupancy and revenue. Our same-store portfolio had 300 basis points of occupancy growth and 26% NOI growth in the quarter. Entry fee sales in 3Q were simply incredible, achieving a new all time high for the quarter.

    在高齡住宅方面,我們社區的生活型態與價值正推動更高的入住率與營收。我們的同店投資組合本季入住率成長 300 個基點,NOI 成長 26%。第三季的入場費(entry fee)銷售表現極為亮眼,創下該季度歷史新高。

  • We've closed $2.2 billion of acquisitions since the IPO and the NOI on these deals is trending in line or ahead of underwriting. Most important to the long-term strategy, we've gone from two operating partners to 13 which dramatically increases Jan's external growth as those partners are now bringing us proprietary acquisitions. Janus success is also driving earnings growth and value creation at Healthpeak given our unique and creative deal structure that aligns the interest of both companies.

    自 IPO 以來,我們已完成 22 億美元的收購,而這些交易的 NOI 走勢與承作假設一致或優於預期。對長期策略最重要的是,我們的營運夥伴已從 2 家增加到 13 家,這大幅提升 Janus 的外部成長,因為這些夥伴現在正為我們帶來專屬的收購機會。由於我們獨特且具創意、能使兩家公司利益一致的交易架構,Janus 的成功也正推動 Healthpeak 的盈餘成長與價值創造。

  • I'll turn it to Kelvin.

    我把時間交給 Kelvin。

  • Kelvin Moses - Chief Financial Officer

    Kelvin Moses - Chief Financial Officer

  • Thank you, Scott. Each of our business segments are running ahead of the plan we set in February and our team on the ground has delivered excellent results, leveraging our relationships to convert demand into executed leases and drive total occupancy gains. Our operating results in the third quarter reflect that execution. We reported FFO as adjusted of $0.44 per share, total same-store cash NOI growth of 3.6% and net debt to adjusted EBITDA of 4.7 times.

    謝謝你,Scott。我們各個業務部門的表現都優於我們在二月所設定的計畫,而我們第一線團隊也交出優異成果,運用我們的關係將需求轉化為已簽署的租約,並推動總入住率提升。我們第三季的營運結果反映了這樣的執行力。我們公布調整後每股 FFO 為 0.44 美元,同店現金 NOI 總成長 3.6%,以及淨負債對調整後 EBITDA 倍數為 4.7 倍。

  • Beginning with outpatient medical. For the quarter, we executed 846,000 square feet of leases, including 218,000 square feet of new leasing and 628,000 square feet of renewals. That brings our year-to-date executions to 3.2 million square feet.

    先從門診醫療談起。本季我們完成了84.6萬平方英尺的租賃簽約,其中21.8萬平方英尺為新租,62.8萬平方英尺為續租。這使我們年初至今的簽約面積達到320萬平方英尺。

  • We delivered another quarter of positive net absorption with new lease commencements that averaged over 11 years and included two large health system and physician practice master leases at attractive rents north of $30 per square foot on a triple net basis.

    我們再度交出一季正向的淨吸納,新增租約起租平均超過11年,並包含兩筆大型醫療體系與醫師診所的總租約(master lease),以三重淨租(triple net)基礎計算,每平方英尺租金具吸引力且高於30美元。

  • Tenant retention increased from last quarter to 81.7% and we achieved cash re-leasing spreads of approximately 5% above our historical averages. Importantly, these renewals come with modest leasing costs of 9.5% of rents on average.

    承租戶留存率較上季提升至81.7%,我們達成的現金再出租價差約較歷史平均高出5%。重要的是,這些續租伴隨的租賃成本溫和,平均約為租金的9.5%。

  • We ended the quarter with total occupancy of 90.3%, which reflects the negative 50 basis points impact from the Brookfield recapitalization and asset sales. On a comparable basis, total occupancy increased sequentially. Heading into the fourth quarter, we expect our leasing velocity to continue with an additional 269,000 square feet of executed leases and 1.03 million square feet of signed LOIs.

    本季期末總入住率為90.3%,其中反映Brookfield資本重整與資產出售帶來的50個基點負面影響。若以可比口徑計算,總入住率較前一季上升。展望第四季,我們預期租賃動能將延續,另有26.9萬平方英尺已完成簽約,並有103萬平方英尺已簽署意向書(LOI)。

  • Turning to lab. During the quarter, we executed 480,000 square feet of leases, our strongest quarter in over a year. That brings our year-to-date executed leases total to over 1 million square feet. These executions represent approximately 70% new leasing, over 80% with biotechnology and R&D tenants and over 40% on vacant space.

    接著談實驗室。本季我們完成48萬平方英尺的租賃簽約,為一年多以來最強的一季。這使我們年初至今的已簽約租賃總量超過100萬平方英尺。這些簽約中約70%為新租,超過80%來自生技與研發(R&D)承租戶,且超過40%發生在空置空間。

  • Subsequent to quarter end, we had an additional 643,000 square feet of executed leases and signed LOIs. From a commencement perspective, we achieved a third consecutive quarter of positive net absorption. The lower rent per square foot on commencements this quarter reflects two large office leases signed in 2025 that carry lower starting rents and lab space but also requires significantly lower TIs.

    在季末之後,我們另有64.3萬平方英尺的已簽約租賃與已簽署LOI。就起租而言,我們連續第三季達成正向淨吸納。本季起租的每平方英尺租金較低,反映兩筆於2025年簽署的大型辦公室租約,其起始租金較低且為辦公空間,但所需的租戶裝修(TI)也顯著較低。

  • Renewal rents this quarter increased to an average of $72 per square foot, up from last quarter with a modest 5.6% roll down on a small sample size caused by a single renewal. Total occupancy during the third quarter increased by 130 basis points sequentially, ending the period at 79.8%.

    本季續租租金平均提高至每平方英尺72美元,較上季上升;在樣本數較小的情況下,因單一續租案導致溫和的5.6%租金下修(roll down)。第三季總入住率較前一季上升130個基點,期末達79.8%。

  • This represents a 270 basis points increase since the start of the year. As we close on the acquisition, Scott referenced, our reported total occupancy base will reset lower given these campuses are 41% occupied today.

    這代表自年初以來增加了270個基點。隨著我們完成Scott所提到的收購案交割,我們的揭露總入住率基準將因這些園區目前僅41%入住而向下重設。

  • We view that availability as embedded upside to capture in submarkets where we have considerable scale and a deep tenant network to draw from. And in senior housing, for the quarter, Janus Living delivered same-store NOI growth of 26%, total revenue growth of 78% and adjusted EBITDA growth of 101%.

    我們將該可供出租面積視為內含的上行空間,可在我們具相當規模、且擁有深厚承租戶網絡的次市場中加以掌握。至於高齡住宅,本季Janus Living同店NOI成長26%,總營收成長78%,調整後EBITDA成長101%。

  • During the quarter and through October, Janus Living completed the acquisition of 39 communities totaling approximately $2.1 billion, bringing the year-to-date acquisition total to $2.9 billion. Healthpeak's ownership totaled 69% of the outstanding shares of Janus Living, which represents roughly $6.1 billion of market value.

    本季以及截至10月,Janus Living完成收購39個社區,總額約21億美元,使年初至今收購總額達29億美元。Healthpeak持有Janus Living流通在外股份的69%,約相當於61億美元的市值。

  • We'll take a moment on the balance sheet before moving on to guidance. While our credit spreads have largely held, borrowing costs have increased through the year due to treasuries and we have taken proactive measures to utilize efficient tools to help mitigate our near-term refinancing costs.

    在進入財測之前,我們先簡要談一下資產負債表。雖然我們的信用利差大致持穩,但由於美國公債殖利率因素,全年借款成本上升;我們已採取前瞻性措施,運用效率較高的工具,以協助降低短期再融資成本。

  • Year-to-date, we have originated two delayed draw term loans, a $400 million term loan, which we expect to draw in the fourth quarter and a $500 million term loan, which we expect to draw in the first quarter of 2027 both priced at SOFR plus 80 basis points, which is inside of where we could issue bonds today.

    年初至今,我們已安排兩筆延遲動用的定期貸款(delayed draw term loans):一筆4億美元定期貸款,預計於第四季動用;以及一筆5億美元定期貸款,預計於2027年第一季動用;兩者定價皆為SOFR加80個基點,低於我們目前發債可能的成本水準。

  • The term loans will reduce our commercial paper balances and provides flexibility as we look to refinance are $1.4 billion in maturities in 2027. We ended the quarter at 4.7 times net debt to adjusted EBITDA. And as of October 30, we had approximately $3.8 billion of liquidity.

    這些定期貸款將降低我們的商業本票(commercial paper)餘額,並在我們著手為2027年到期的14億美元債務再融資時提供彈性。本季期末,我們的淨負債對調整後EBITDA倍數為4.7倍。截至10月30日,我們約有38億美元的流動性。

  • And finally, guidance. We raised our FFO as adjusted guidance for the third consecutive quarter by $0.02 at the midpoint to a range of $1.76 to $1.78 per share. The update to our guidance reflects stronger leasing across the portfolio, the delayed timing of our remaining dispositions and highlights the strength of our operating performance year-to-date, including a 50 basis points increase to total same-store at the midpoint to a range of 0.5% to 2.0%.

    最後是財測。我們連續第三季上調調整後FFO指引,中位數上調0.02美元至每股1.76至1.78美元區間。本次指引更新反映投資組合整體租賃表現更強、剩餘處分案時點延後,並凸顯我們年初至今營運表現的韌性;其中同店總體在中位數上調50個基點至0.5%至2.0%的區間。

  • Our increase to same store includes a 25 basis points increase in outpatient medical to 2.5% to 3%, a 100 basis points increase in lab to down 3% to down 6% and a 250 basis points increase in senior housing to 16% to 19%.

    同店上調內容包括:門診醫療上調25個基點至2.5%至3%;實驗室上調100個基點至下滑3%至下滑6%;高齡住宅上調250個基點至16%至19%。

  • With that, operator, please open the line for Q&A.

    以上,接線員,請開放電話進入問答。

  • Operator

    Operator

  • (Operator Instructions)

    (接線員指示)

  • Richard Anderson, Cantor Fitzgerald.

    Richard Anderson,Cantor Fitzgerald。

  • Richard Anderson - Analyst

    Richard Anderson - Analyst

  • Hey, thanks. Good morning, team. So Scott, I wanted to ask you about the life science acquisition strategy are unique in the way that they blend into what you already have. I'm curious if you could communicate a pipeline of opportunities, whether you get [0%] or 100% of them in the future?

    嗨,謝謝。各位早安。Scott,我想請教你們的生命科學收購策略,它的獨特之處在於能與你們既有資產相互融合。我想了解你是否能談談機會管線的情況,以及未來你們可能拿到其中[0%]或100%的機會?

  • Like how active is the pipeline coming at you, given that you're the only game in town in terms of being a reasonable acquirer of life science assets? Thanks.

    考量到你們在生命科學資產方面幾乎是市場上唯一合理的收購方,現在送到你們面前的案源管線有多活躍?謝謝。

  • Scott Brinker - President, Chief Executive Officer, Director

    Scott Brinker - President, Chief Executive Officer, Director

  • Thanks, Rich. Yeah, I think I can comment overlap in the acquisitions we've done year-to-date as well as what's under contract is that they're cheap on a price per foot basis but also strategic. Usually, when you're buying assets you get one, but not the other. If it's strategic, it's usually expensive, it's cheap, it's usually not strategic.

    謝謝,Rich。是的,我想我可以評論一下我們年初至今已完成的收購,以及目前在合約中的案子:它們在每平方英尺價格上很便宜,但同時也具策略性。通常你買資產只能得到其中一項,而不是兩者兼具。如果具策略性,通常就很貴;如果很便宜,通常就不具策略性。

  • Just a unique point in time in life science, in particular, where we can buy assets that are cheap and strategic. And that's what we've done. So $1 billion, plus or minus, of acquisitions either closed or in the pipeline. If you look at them on a map, they're essentially part of an existing healthy campus. So we really have no interest in going into submarkets where we have no competitive advantage.

    生命科學領域目前正處於一個相當特殊的時間點,讓我們能買到既便宜又具策略性的資產。而這正是我們所做的。大約10億美元、上下浮動的收購案,已完成或在管線中。如果你把它們放到地圖上看,基本上都屬於既有且健康園區的一部分。因此,我們完全沒有興趣進入我們沒有競爭優勢的次市場。

  • The whole idea here is to buy things cheaply that are not leasing up today for one reason or another, in bringing our team, our tenant network, our balance sheet, our credibility to the table to lease them up, it is working.

    整個想法是:以低價買進因某些原因目前尚未順利出租的資產,並把我們的團隊、承租戶網絡、資產負債表實力與市場信譽帶到桌面上來把它們租出去;而且這套做法正在奏效。

  • We've made tremendous progress at Gateway. The campus in South San Francisco with Scott and the team, and we expect to do the exact same with these three acquisitions. The fact is very unique in that we have significant leasing traction on about of 70% of the acquired vacancy in some cases, before we even formally closed the acquisition.

    我們在Gateway已取得巨大進展。在南舊金山的園區,Scott和團隊一起推進,我們也預期會在這三筆收購案上如法炮製。事實上非常獨特的是:在某些情況下,我們甚至在正式完成收購交割之前,就已在約70%的收購空置面積上取得顯著的租賃進展。

  • So really amazing traction on those, and we feel like it's the price that we're buying these. They're just a significant margin of safety. We're underwriting them at today's rents. I think you can paint a component picture given the difficulty of bringing new development anytime soon given replacement costs (technical difficulty) rents to run once occupancy does recover, and it's clearly on that trajectory.

    所以這些資產的承接動能真的非常驚人,我們覺得我們買進的價格就是關鍵。它們提供了非常可觀的安全邊際。我們是以今天的租金水準來做承銷評估。我認為,考量到替代成本(技術難度)使得短期內很難推出新的開發案,一旦入住率回升,租金就會上行;而且很明顯正朝那個方向發展。

  • So we've said for a while, we're going to be a consolidator. That's proving to be correct. We've got a highly valued outpatient business that's allowing us to recap at really strong prices and redeploy into assets at essentially the same initial yield with vastly higher stabilized yields. We're making great progress towards that goal. So, next question.

    所以我們講了一段時間,我們會成為整併者。事實證明這個判斷是正確的。我們擁有估值很高的門診業務,讓我們能以非常強的價格進行再資本化,並把資金重新配置到資產上,在本質上相同的初始收益率下,取得高得多的穩定後收益率。我們正朝這個目標取得很大進展。所以,下一個問題。

  • Operator

    Operator

  • Michael Carroll, RBC Capital Markets.

    Michael Carroll,RBC Capital Markets。

  • Michael Carroll - Analyst

    Michael Carroll - Analyst

  • Yeah, thanks. Scott, I wanted to touch on your comments answering the last question. I believe you said that DOC has good targets on 70% of the acquired vacancy. I mean how far along are those conversations? And in your underwriting, when do you assume that these assets reach stabilized occupancy?

    好的,謝謝。Scott,我想接續你回答上一題時的評論。我記得你說 DOC 對於已收購空置面積中的 70% 有不錯的目標對象。我的意思是,那些對話進行到什麼程度了?另外在你們的承銷假設中,你們預期這些資產何時能達到穩定入住率?

  • Scott Brinker - President, Chief Executive Officer, Director

    Scott Brinker - President, Chief Executive Officer, Director

  • We're generally underwriting these in the two- to three-year range to fully lease up. And we're pretty far along in those conversations. So I would call it active negotiations comprising that 70%. Next question.

    我們一般在承銷上假設需要兩到三年才能完全出租完畢。而且我們在那些對話上已經推進得相當深入。所以我會把那 70% 形容為正在進行中的積極談判。下一個問題。

  • Operator

    Operator

  • Jamie Feldman, Wells Fargo.

    Jamie Feldman,Wells Fargo。

  • Jamie Feldman - Analyst

    Jamie Feldman - Analyst

  • Great. Maybe just adds to the prior line of questioning. Just as we think about '27, can you talk us through what's baked in terms of leases that have been signed when they come in? And the net of move-outs just what that NOI stream is going to look like from some of the acquisition activity or even just some of the leasing activity?

    很好。也許延續前面那條提問脈絡。就我們思考 2027 年而言,你能否帶我們梳理一下:已簽署的租約在何時開始貢獻?以及扣除搬出後,從一些收購活動、甚至只是一些出租活動來看,那條 NOI(淨營運收入)流會長什麼樣子?

  • Kelvin Moses - Chief Financial Officer

    Kelvin Moses - Chief Financial Officer

  • This is Kelvin and I'll jump in there. We've done a pretty tremendous job I'd say, this year from a leasing perspective. We've got about 1 million square feet of lease executions year-to-date. And as we mentioned in the prepared remarks, another 640,000 square feet under LOI are executed post quarter end.

    我是 Kelvin,我來補充一下。我會說,今年從出租角度來看,我們做得相當出色。截至目前為止,我們已完成約 100 萬平方英尺的租約簽署。而且如同我們在事先準備的講稿中提到的,季末之後又有另外 64 萬平方英尺在 LOI(意向書)下完成簽署。

  • So pretty tremendous progress and these leases probably require 12 to 15 months depending on the build out of the space and the specific requirements of that tenant before they're able to flow through into NOI and subsequently earnings.

    所以進展非常顯著;而這些租約通常需要 12 到 15 個月(視空間裝修與該租戶的具體需求而定),之後才能反映到 NOI,進而反映到盈餘。

  • Keep in mind, as we execute these leases, there are free rent periods as well that factor into the timeline of when you start to see that cash flow in. But from an earnings perspective, you'll see over the next couple of quarters, the execution that we've had over the last few quarters start to flow in, but it's a 12- to 15-month process to get those spaces into a position for occupancy.

    請記住,當我們簽下這些租約時,通常也會有免租期,這也會影響你開始看到現金流入的時間點。但從盈餘角度來看,接下來幾個季度,你會看到我們過去幾個季度的簽約開始逐步反映;不過要讓那些空間具備可入住狀態,整體仍是 12 到 15 個月的流程。

  • Operator

    Operator

  • Ronald Kamden, Morgan Stanley.

    Ronald Kamden,Morgan Stanley。

  • Ronald Kamden - Analyst

    Ronald Kamden - Analyst

  • Hey, great. Just staying on the lab piece. Just looking at the same-store NOI, asking the question in a different way. Does this feel like it's an inflection point from here as you talked about leases commencing obviously, 12 to 15 months. But [there] puts and takes as you're thinking about the same-store NOI going forward and then is an inflection point? Thanks.

    嗨,很好。我想繼續聚焦在實驗室這一塊。我看同店 NOI,用另一種方式問同一個問題。你們提到租約開始生效顯然需要 12 到 15 個月;從現在開始,這是否感覺像是一個拐點?另外,當你們思考未來同店 NOI 的走勢時,有哪些拉動與抵消因素?以及是否就是一個拐點?謝謝。

  • Kelvin Moses - Chief Financial Officer

    Kelvin Moses - Chief Financial Officer

  • Hey, Ron. This is certainly a base that we can grow from. I think we've been saying our focus for purposes of really guiding investors towards NOI growth and subsequently, earnings growth has been total occupancy and to be able to achieve 130 basis points of occupancy capture this quarter, 270 basis points on the year.

    嗨,Ron。這確實是一個我們可以在其上成長的基礎。我想我們一直在說,我們引導投資人理解 NOI 成長、進而盈餘成長的重點在於總入住率;而本季能夠提升 130 個基點的入住率、年初至今提升 270 個基點。

  • Certainly, putting us in the position to see NOI growth over the subsequent quarters as these leases commence and the tenants start paying rent. So we're certainly on the right path for future NOI growth here in the lab business.

    這當然讓我們處於一個有利位置:隨著這些租約開始生效、租戶開始支付租金,後續幾個季度就能看到 NOI 成長。所以在實驗室業務上,我們確實走在未來 NOI 成長的正確道路上。

  • Operator

    Operator

  • Nick Yulico, Scotiabank.

    Nick Yulico,Scotiabank。

  • Nicholas Yulico - Analyst

    Nicholas Yulico - Analyst

  • Thanks. Just going back to the lab. Given that you're about 80% occupied in lab, and you already have vacancy in the existing submarkets where you did the acquisitions. Maybe you could just talk about why you think it makes sense to be adding more vacancy exposure to the portfolio? And within those different submarkets as well, if you could just talk about how like [HQ] points that building's position versus the vacancy you have next door Directors Science Park.

    謝謝。回到實驗室的問題。鑑於你們的實驗室目前約 80% 入住,而且你們在進行收購的既有子市場中本來就有空置。也許你們可以談談,為什麼你們認為在投資組合中增加更多空置曝險是合理的?另外在不同子市場中,也請談談像 [HQ] Point 這棟樓的定位,相較於你們隔壁 Directors Science Park 的空置狀況。

  • And then similarly, 100 Acorn, you've owned the asset and the JV, there's been vacancy. Why do you feel better about it. leasing it now and then in South San Francisco, 5,000 shoreline, you also have redev?elopment projects right next door. So just -- how you could talk about the positioning of that space? Thanks.

    同樣地,100 Acorn 這個資產你們在合資(JV)中已持有一段時間,也一直有空置。為什麼你們現在對把它租出去更有信心?另外在南舊金山,5,000 Shoreline,你們隔壁也有再開發(redev?elopment)專案。所以——你們能否談談那個空間的定位?謝謝。

  • Scott Brinker - President, Chief Executive Officer, Director

    Scott Brinker - President, Chief Executive Officer, Director

  • Yeah, there were a few questions there. I'll try to address most of them. I may ask Scott [Bohn's] to jump in as well. But we think we're buying opportunity at a really cheap price. So the more we can do, the better because we are trending positively, and there's a lot of upside to capture here.

    是的,裡面有幾個問題。我會盡量回答大部分。我也可能請 Scott [Bohn's] 一起補充。但我們認為我們是在以非常便宜的價格買進機會。所以我們能做得越多越好,因為我們的趨勢正在改善,而且這裡有很大的上行空間可以掌握。

  • I'm not sure how many commercial real estate sectors there are where you can buy super core assets that stabilize in the 9% to 10% range. I mean that sounds like a development plus-plus type return with a lot less risk.

    我不確定有多少商用不動產類別,能讓你買到超核心資產,且穩定後報酬率可落在 9% 到 10% 的區間。我的意思是,這聽起來像是「開發 plus-plus」等級的回報,但風險要小得多。

  • And you have to think about these local markets as ecosystems, what's happening in the Bay Area has nothing to do with what's happening in San Diego or Boston and the more local scale we have, the more competitive our entire footprint is.

    而且你必須把這些在地市場視為生態系;灣區發生的事情,與聖地牙哥或波士頓發生的事情毫無關聯。我們在地方尺度上的布局越大,我們整體版圖的競爭力就越強。

  • So it's not a single asset, although each of these could stand alone as strong investments. You have to think about the impact on our entire ecosystem. Like I said earlier, we're the only group that's actually growing. We're doing it pretty significantly in markets where we already have a strong competitive position, and that's only getting stronger with these transactions.

    所以這不是單一資產的問題,雖然每一個都可以獨立成為很強的投資。你必須思考它對我們整個生態系的影響。就像我先前說的,我們是唯一實際在成長的團隊。我們在本來就具備強勢競爭地位的市場中,以相當顯著的幅度擴張,而這些交易只會讓我們的優勢更強。

  • You asked about HQ Point. That's a bigger building, bigger floor place, bigger users than we can accommodate at our Directors Place campus that's right next door. So that's an easy way to distinguish that building from what we have in the marketplace today.

    你問到 HQ Point。那是一棟更大的建築,樓層平面更大,使用者規模也更大,超出我們隔壁 Directors Place 園區所能容納的範圍。所以這是一個很容易把那棟樓與我們目前市場上既有產品區隔開來的方法。

  • The building in South San Francisco is a smaller availability vacancy in terms of the size of the building. So that's really not competing with our existing development and redevelopment portfolio, and there's a tenant in the building already that's growing pretty fast. So that's a totally unique building.

    南舊金山那棟樓,就建築規模而言,可供出租的空置面積較小。所以它其實不會與我們既有的開發與再開發投資組合競爭;而且那棟樓裡已經有一個租戶,成長速度相當快。所以那是一棟完全獨特的建築。

  • And then the building in Cambridge, remember, we were in a JV, but we were not leasing or property managing that portfolio. So that transaction closes, we'll be able to take over the leasing and the property management and hopefully drive better leasing outcome.

    接著是劍橋那棟大樓,記得我們當時是在一個合資(JV)裡,但我們並沒有負責該投資組合的出租或物業管理。所以等那筆交易完成後,我們就能接手出租與物業管理,並希望能帶動更好的出租成果。

  • There's also financing on that deal today, which, as I said in the earlier answer, that does restrict an owner's ability to move quickly and make decisions and meet the market where it is. So hopefully, having an unencumbered property as well as the fact that we'll be leasing it in property managing will be the difference maker there. Okay, next question.

    另外,那筆交易目前也有融資,如我在前一題回答中提到的,這確實會限制業主快速行動、做決策並依市場現況調整的能力。所以希望在資產解除負擔(unencumbered)之後,再加上我們將負責出租與物業管理,能成為關鍵差異。好,下一題。

  • Operator

    Operator

  • Juan Sanabria, BMO Capital Markets.

    Juan Sanabria,BMO Capital Markets。

  • Juan Sanabria - Analyst

    Juan Sanabria - Analyst

  • Good morning. Thanks for the time. Clearly, things are improving in lab leasing but hoping you could talk a little bit about any known move-outs or how the tenant credit profile, any bad debt updates you could provide as an offset just to make sure, we're correctly tempering our enthusiasm going forward. If you could just give a comment on those two items, that would be great?

    早安。謝謝撥冗。顯然實驗室出租狀況正在改善,但想請你們談談是否有任何已知的退租(move-outs),或是承租戶的信用概況、以及是否有任何壞帳(bad debt)更新可以提供,作為一個抵銷因素,確保我們在展望未來時能適度調整樂觀程度。如果能就這兩點做個評論就太好了?

  • Kelvin Moses - Chief Financial Officer

    Kelvin Moses - Chief Financial Officer

  • Juan, yeah, happy to jump in. I'd say at this point, we're working towards continuing to execute on our stated leasing objectives really looking at 2027 and working through renewals that we can pull forward. We've done a really great job of that over the last 15 or so months really addressing some of the early renewals there. So that plan continues.

    Juan,是的,我很樂意先回應。我想目前我們正持續朝既定的出租目標執行,重點放在展望到2027年,並推進我們可以提前處理的續約。過去大約15個月,我們在這方面做得非常好,確實處理了一些提前續約。所以這個計畫會持續進行。

  • And then from a credit perspective, I'd say there's probably been over $150 billion of capital flowing into the biotech space between IPOs, M&A, secondary offerings, and we're certainly seeing that benefit in the demand and our pipeline.

    再從信用面來看,我會說目前大概有超過1,500億美元的資金流入生技領域,來源包括IPO、併購(M&A)、增資發行(secondary offerings),我們也確實在需求與我們的案源(pipeline)中看到這樣的助益。

  • The pipeline has been strong, extremely healthy, and our existing tenants have been able to access the capital markets where they've had positive data outcomes in their business. So the credit profile overall within our lab portfolio has meaningfully improved.

    案源一直很強勁、非常健康,而我們現有的承租戶在其業務數據結果正向時,也能進入資本市場取得資金。因此,我們實驗室投資組合內的整體信用概況已明顯改善。

  • And we're looking forward to capitalizing on that pipeline or rather -- further capitalizing on that pipeline to drive net absorption through the business. So a lot of positives that we've been seeing, we've been echoing that same sentiment for the balance of the year and it continues.

    我們也期待能把握這個案源,或者說——進一步把握這個案源,來推動業務的淨吸納(net absorption)。所以我們看到很多正面訊號;我們在今年剩餘期間也一直傳達相同的看法,而且趨勢仍在延續。

  • Operator

    Operator

  • [Sidney McEntee, JP Morgan].

    [Sidney McEntee,JP Morgan]。

  • Sidney McEntee - Analyst

    Sidney McEntee - Analyst

  • Hi, guys. So on the transaction market, given the recent rate volatility, have you guys seen cap rates move across the different asset classes? And has it changed at all how you think about sourcing more distressed deals or the composition of the pipeline overall?

    嗨,各位。關於交易市場,鑑於近期利率波動,你們是否看到不同資產類別的資本化率(cap rates)有所變動?以及這是否改變了你們對於尋找更多困境交易(distressed deals)或整體案源組成的看法?

  • Scott Brinker - President, Chief Executive Officer, Director

    Scott Brinker - President, Chief Executive Officer, Director

  • Yeah, it's definitely been volatile. I mean the tenure goes from 4% to 4.5% to 5% plus and now back to around 5%. I wouldn't be surprised if the transaction market slows down a little bit. Across all commercial real estate, but including health care, given that volatility and people are just trying to understand what their cost of capital is especially a levered buyer that's using 60% to 70% financing, not a pretty big impact.

    是的,確實非常波動。我的意思是,10年期利率從4%到4.5%到5%以上,現在又回到大約5%。我不會意外交易市場會稍微放緩一些。整體商用不動產都是如此,醫療保健也包含在內;在這種波動下,大家都在試著搞清楚自己的資金成本,尤其是使用60%到70%融資的槓桿買方,影響非常大。

  • On asset values. So I wouldn't be surprised to see a bit of a slowdown. I think some sectors will be more impacted than others. You think about a lower growth, longer lease term portfolio or asset that probably is more impacted by the change in rates, a sector like senior housing, probably a little bit less just given the growth profile.

    對資產價值也是如此。所以我不會意外看到交易活動稍微降溫。我認為有些產業受影響會比其他產業更大。你想想看,成長較低、租期較長的投資組合或資產,可能更容易受到利率變動影響;像是高齡住宅(senior housing)這類板塊,因為成長性較高,可能受影響會小一些。

  • But TBD, there has been a lot of volatility and these transactions take, I don't know, six months, plus or minus. From start of discussions until the closing. So anything that's happening now has negotiated a long time ago that it's hard to say, and we'll be precise, but we certainly are aware of a lot of transactions across commercial real estate that are [been] put on pause or buyers attempting to re-trade.

    但仍有待觀察(TBD)。波動很大,而這些交易通常需要,我不知道,大概六個月左右,上下浮動。從開始討論到完成交割。所以現在發生的任何事,其實很久以前就談好了,很難精準判斷;但我們確實注意到,商用不動產領域有很多交易被按下暫停,或買方嘗試重新議價(re-trade)。

  • We have not done that. We commit to something, and we honor the price that we provided, but we think that we negotiated a really compelling price in the first place, which allows us to move forward.

    我們沒有這麼做。我們一旦承諾,就會遵守我們提出的價格;而且我們認為一開始就談到了一個非常有吸引力的價格,讓我們能夠繼續推進。

  • Operator

    Operator

  • Michael Goldsmith, UBS.

    Michael Goldsmith,UBS。

  • Michael Goldsmith - Analyst

    Michael Goldsmith - Analyst

  • Good morning. Thanks a lot for taking my question. Scott, you mentioned AI can [fill] robotics uses is number due versus demand. Can you give us a sense of how meaningful that is within the current pipeline? And is that truly incremental demand for last otherwise compete with traditional users? Or is it primarily absorbing space that would be more difficult to lease? Thanks.

    早安。非常感謝讓我提問。Scott,你提到AI可以[fill]機器人用途是數量到期相對於需求。你能否讓我們了解,這在目前案源中有多重要?而這是否真的是增量需求,否則會與傳統使用者競爭?或者它主要是在吸收那些原本更難出租的空間?謝謝。

  • Scott Bohn - Chief Development Officer and Head of Lab

    Scott Bohn - Chief Development Officer and Head of Lab

  • Michael, this is Scott Bohn. I can take that one. From a demand perspective, leasing to biotech's are bread and butter, right? If you look at our pipeline, it's still over 75% biotech, whether it be public or private, but there is a significant amount of increased demand from the robotics across all three markets.

    Michael,我是Scott Bohn。我來回答這題。從需求面來看,出租給生技公司是我們的核心業務,對吧?如果你看我們的案源,仍有超過75%是生技,不論是上市或未上市;但在三個市場中,來自機器人領域的需求確實顯著增加。

  • I think the epicenter of that is San Francisco, where we've seen the most of it. So there is purely incremental demand from that -- in taking additional space in -- we're in active discussions and deals on several of those users, where we've got space that was either a shell condition or wasn't built out as lab that we can do a deal at a much lower CI and a very competitive rent economics makes sense to do [you] like that.

    我認為其中的中心點是在舊金山,我們在那裡看到最多。所以這確實是純粹的增量需求——他們在承租額外空間;我們正與其中幾個使用者進行積極洽談並推進交易,我們手上有一些空間原本是毛胚(shell)狀態或並未裝修成實驗室,我們可以用更低的資本投入(CI)完成交易,並以非常具競爭力的租金經濟條件來做這類交易是合理的。

  • And it's also taking a lot of the spaces buildings that were set to be converted to lab in the periphery that probably never should have been converted to lab frankly and taking those out of the new supply numbers.

    同時,這也吸收了許多原本計畫在周邊地區改造成實驗室的空間與建物;坦白說,那些可能本來就不該改成實驗室,這也把它們從新增供給的數字中剔除。

  • Operator

    Operator

  • Farrell Granath, Bank of America.

    Farrell Granath,Bank of America。

  • Farrell Granath - Analyst

    Farrell Granath - Analyst

  • Good morning. Thank you for taking my question. I wanted to go back to the three transactions that we've been speaking about. If you can touch on the pricing dynamics as well as really the equity and debt or basis that you were able to really structure these deals? And how does that give you a preference, I guess, going forward of how you would like to potentially do other opportunistic deals?

    早安。謝謝讓我提問。我想回到我們一直在談的那三筆交易。如果可以的話,請談談定價動態,以及你們在股權與債務、或成本基礎(basis)方面是如何架構這些交易的?以及這如何讓你們在未來、在可能進行其他機會型交易時,對偏好的做法有所取向?

  • Scott Brinker - President, Chief Executive Officer, Director

    Scott Brinker - President, Chief Executive Officer, Director

  • Yeah, for the last two to three years, when we consider making investments in life science, they tended to be more structured investments because we didn't feel like the prices to buy an asset fee simple had fallen by enough to make it worthwhile for us.

    是的,過去兩到三年,當我們考慮在生命科學領域投資時,通常會偏向結構型投資,因為我們覺得以完全所有權(fee simple)買入資產的價格下跌幅度還不夠,不足以讓我們覺得值得。

  • So we did some mortgage lending. We did one preferred stock investment. We feel like in 2026, the prices have come down to a point on a per foot basis that even at today's market rents, we can underwrite a really compelling stabilized return. And therefore, we've shifted towards doing fee simple acquisitions in 2026.

    所以我們做了一些抵押貸款放款。也做過一筆優先股投資。我們認為到了2026年,價格已經在每平方英尺的基礎上下降到一個程度,即使以目前的市場租金,我們也能承作出非常有吸引力的穩定後報酬(stabilized return)。因此,我們在2026年已轉向進行完全所有權(fee simple)的收購。

  • The dynamics of each deal were a little different. The lender in Cambridge essentially gets out at par, but with very little left for the equity on the other two transactions, the lenders, the first mortgage lenders took a modest loss. So we were negotiating directly with them. Next question.

    每筆交易的動態都有些不同。在劍橋那筆交易中,放款人基本上以面值(par)退出,但股權端所剩無幾;而在另外兩筆交易中,第一順位抵押貸款人承擔了小幅損失。因此我們是直接與他們談判。下一題。

  • Operator

    Operator

  • Nick Joseph, Citi.

    Nick Joseph,花旗。

  • Nick Joseph - Analyst

    Nick Joseph - Analyst

  • Thanks. You mentioned that's a great time to be a buyer. You talked about the attractive stabilized returns and the timeline for achieving that. Why don't you think you've seen more competition for life science assets? Maybe you could just touch on the buyer pool broadly in the lending environment?

    謝謝。你提到現在是當買方的好時機。你談到具吸引力的穩定化報酬,以及達成該目標的時間表。為什麼你認為生命科學資產沒有出現更多競爭?也許你可以在目前放貸環境下,概括談談買方族群的情況?

  • Scott Brinker - President, Chief Executive Officer, Director

    Scott Brinker - President, Chief Executive Officer, Director

  • Hey, Nick, I think it's mostly that so many people lost so much money in the last four years, it became a pretty hot sector to participate in, so starting in 2017, '18, '19 and then got turbocharged in 2020 and '21. So there are a lot of new entrants, both GPs, LPs and lenders. And obviously, they did not have a good outcome.

    嗨,Nick,我認為主要是因為過去四年有太多人虧了太多錢。這個產業一度成為相當熱門、大家都想參與的領域,從2017、2018、2019開始,然後在2020與2021被加速推升。因此出現了很多新進者,包括普通合夥人(GP)、有限合夥人(LP)以及放款機構。而很明顯地,他們的結果並不好。

  • Some did okay but a lot of people certainly lost a lot of money, and it will take time for those scars to deal. It's still a bad word life science in most real estate shops around the country. And maybe for a good reason, if they came in without a platform to drive performance and the competitive advantage that a company like Healthpeak has, I think they're going to have a hard time even in today's market which is clearly improving.

    有些人表現還可以,但很多人確實虧了不少錢,而這些傷痕需要時間才能淡化。在全國多數房地產機構裡,「生命科學」仍然是個不太好聽的詞。而且也許有其道理:如果他們進來時沒有能驅動績效的平台,以及像Healthpeak這樣公司所具備的競爭優勢,我認為即便在今天這個明顯正在改善的市場裡,他們也會很難做得好。

  • So I think it's just a niche business that requires an existing footprint to give tenants flexibility to have the credit ability to own, operate, develop very specialized real estate and then the tenant relationships, not just the tenants, but the venture capital firms themselves who are driving a lot of those decisions.

    所以我認為這就是一門利基型生意,需要既有的佈局,才能讓租戶有彈性;也需要具備信用能力去持有、營運、開發非常專業的房地產;還需要租戶關係——不只是租戶本身,還包括創投基金,因為很多決策是由他們推動的。

  • I think all of that, just makes us a unique business where it's not just real estate, it's not just having capital. Those things are important. You also have to have the platform, and we've got all three. Next question.

    我認為上述這些,使我們成為一個獨特的事業:不只是房地產,也不只是有資金。那些都很重要。你還必須有平台,而我們三者兼具。下一題。

  • Operator

    Operator

  • Michael Stroyeck, Green Street.

    Michael Stroyeck,Green Street。

  • Michael Stroyeck - Analyst

    Michael Stroyeck - Analyst

  • Thanks, and good morning. Maybe one question on the $200 million of additional outpatient asset sales outlined in the presentation. Can you just provide a bit of color on the types of assets you're selling and how they compare to your in-place portfolio? And then you guys called out 7% cap rates on those assets. I imagine they were negotiated several months ago. Do you think that they're negotiated today, you'd be able to achieve similar pricing?

    謝謝,早安。想問一下簡報中提到額外2億美元的門診資產出售。你能否補充一些細節,說明你們要賣的資產類型,以及它們與你們現有投資組合相比如何?另外你們提到這些資產的資本化率(cap rate)為7%。我猜這些交易是幾個月前談定的。你認為如果今天重新談判,是否仍能達到類似的價格?

  • Scott Brinker - President, Chief Executive Officer, Director

    Scott Brinker - President, Chief Executive Officer, Director

  • Hard to say, Michael. That's our contract with money at risk, so we felt comfortable publishing it. But we had a portfolio in the Southeast where the health system was debating whether or not to renew the lease, it's actually four buildings. And we ultimately decided rather than renewing the lease that we go ahead and sell those.

    很難說,Michael。那是我們已簽約、且有資金承擔風險的合約,所以我們才有把握對外公布。我們在美國東南部有一個投資組合,當地的醫療體系正在考慮是否續租,實際上是四棟建物。最後我們決定與其續租,不如直接把它們賣掉。

  • They weren't particularly strategic for us in the scheme of things, and they offered a fair and reasonable price for those particular assets. I'd say they're below average in terms of asset quality and we were willing to transact at that price. So that one should be done by year-end.

    就整體策略而言,它們對我們並不是特別關鍵,而對方對這些特定資產提出了公平合理的價格。我會說就資產品質而言,它們低於平均水準,因此我們願意以那個價格成交。所以這筆交易應該會在年底前完成。

  • Operator

    Operator

  • Dave Rodgers, Raymond James.

    Dave Rodgers,Raymond James。

  • Dave Rodgers - Analyst

    Dave Rodgers - Analyst

  • Yeah, good morning. Obviously, getting more comfortable putting equity into the life science acquisitions that you've done probably tells us that you're also getting a little more comfortable with where pricing for lease deals is. So I'm curious, I think in the quarter, you said negative 5%, 6% was the lab spread, but maybe that was one deal that Kelvin noted as opposed to a broader transaction market for you guys.

    是的,早安。很明顯,你們對於把股權投入到已完成的生命科學收購案更有信心,這大概也表示你們對租賃交易的定價水準更有把握。所以我很好奇,我記得你們在本季提到實驗室租賃價差(lab spread)為負5%、負6%,但也許那只是Kelvin提到的一筆交易,而不是你們更廣泛的交易市場狀況。

  • So can you give us a better sense for where maybe face rates and were economic rents have moved or are moving in the life science business and how that compares to where you guys see your existing in-place rents across the three major markets?

    所以你能否更清楚說明,在生命科學業務中,名目租金(face rates)以及經濟租金(economic rents)已經如何變動或正在如何變動?以及這與你們在三大主要市場現有、已在帳的租金水準相比如何?

  • Scott Bohn - Chief Development Officer and Head of Lab

    Scott Bohn - Chief Development Officer and Head of Lab

  • Sure. I can take that one. This is Scott Bohn. [Where] I get -- I think I'd probably start in Boston. Probably the most pressure on deal economics still in Boston, just given the supply demand imbalance is probably still the greatest there. I would say our portfolio there is mid-80s occupied or very little lease roll over the next 12 to 18 months.

    當然。我來回答。我是Scott Bohn。[就我看]——我想我會先從波士頓談起。就交易經濟條件而言,波士頓的壓力可能仍然最大,主要是因為供需失衡在那裡可能仍最為嚴重。我會說我們在那裡的投資組合入住率在80%中段,而且未來12到18個月幾乎沒有租約到期。

  • So we feel like we're in a good position, though. And our assets are in the top submarkets where the lion's share of the demand has been. So we've actually been able to do pretty well in the leasing that we've done there.

    因此我們覺得自己處於不錯的位置。而且我們的資產位於最核心的子市場,需求大多集中在那些區域。所以我們在那裡所做的租賃其實表現得相當不錯。

  • San Diego, as Scott mentioned, we've brought Torrey Pines to 100% in our portfolio. So we'll have additional pricing power there as we look to any renewals in the near term in that market. And then in the Bay Area, we continue to work through our dominant position there. And a lot of the deals we do in the Bay Area are deals that -- are with our existing tenants moving pieces around the chessboard and where we tend to do better than the market on the rental rates.

    至於聖地牙哥,如Scott提到的,我們已把Torrey Pines在我們投資組合中的入住率提升到100%。因此在該市場短期內面對任何續租時,我們將擁有更高的定價能力。而在灣區,我們持續運用我們在那裡的主導地位。我們在灣區做的許多交易——是與現有租戶在「棋盤上」調整配置的交易,而在租金水準上我們往往能比市場做得更好。

  • So I think there's signs of evening out a little bit on the landlord and tenant side in pockets, but it's very deal dependent. You're still looking at every deal is different, depending on the tenant, the space, how much capital is going in term and all those things. So it's hard to pay with a pretty broad brush on market rents across the market because it is very deal specific today.

    所以我認為在某些區域,房東與租戶之間的力量正在稍微趨於均衡,但這非常取決於個案。你仍然會看到每一筆交易都不同,取決於租戶、空間、投入多少資本、租期以及所有這些因素。因此很難用很概括的方式去描述整體市場租金,因為今天它非常「一案一議」。

  • Scott Brinker - President, Chief Executive Officer, Director

    Scott Brinker - President, Chief Executive Officer, Director

  • We've had even a few situations in recent months where we have multiple tenants bidding for the same suite or building, which we haven't seen in many years. So the market doesn't have to get back to 95% to create that dynamic. It's a tenant that wants to be in our portfolio or has an existing lease with us. It does help create attention on the leasing economics that should turn favorable for us.

    甚至在最近幾個月,我們也遇到過少數情況:有多個租戶同時競標同一個套間或同一棟大樓,這是我們多年未見的。所以市場不必回到95%的入住率才會出現那種動態。只要是想進入我們投資組合的租戶,或是已經與我們有既有租約的租戶,就可能出現。這確實有助於讓租賃經濟條件的談判更有利於我們。

  • And I just reiterate that we're underwriting the acquisitions to today's current market rents and TIs. So it's not like we're underwriting some big improvement, although we do think that's possible in the years ahead. Next question.

    我再重申一次:我們在承作這些收購案時,是以當前市場租金與租戶裝修(TI)水準來做承作假設。因此並不是在假設會有很大的改善,雖然我們確實認為未來幾年有這種可能。下一題。

  • Operator

    Operator

  • (Operator Instructions)

    (接線員指示)

  • Austin Wurschmidt, KeyBanc Capital Markets.

    Austin Wurschmidt,KeyBanc Capital Markets。

  • Austin Wurschmidt - Analyst

    Austin Wurschmidt - Analyst

  • Hi, good morning, everyone. I have a two-parter. One, just clarifying what does the 9% to 10% stabilized returns assumed for stabilized occupancy? And then separately, maybe Kelvin, based on the 4Q implied guidance of $0.42 getting to an annualized rate of $1.68 realize you're not providing guidance, but any high-level thoughts that you could share around puts and takes next year that we should be thinking about? Thanks.

    嗨,各位早安。我有兩個問題。第一,想確認你們假設的9%到10%穩定化報酬,是以多少的穩定化入住率為前提?第二,Kelvin,基於第四季指引隱含每股0.42美元、年化為1.68美元——我知道你們不提供指引,但你能否分享一些高層次看法,談談明年我們應該考量哪些正負因素(puts and takes)?謝謝。

  • Scott Brinker - President, Chief Executive Officer, Director

    Scott Brinker - President, Chief Executive Officer, Director

  • Yeah, Austin on the occupancy, and then I'll turn it to Kelvin, like we underwrote gateway in the mid-80s. I think these three were more in the 90% range. But just given the size of leases in the life science space, the more likely scenarios you're either 100% or you're something below 75%. They tend to be chunky, but we have built in a pretty sizable vacancy in most of these acquisitions we've done. Kelvin?

    好的,Austin,先談入住率,然後我再交給Kelvin。像我們對Gateway的承作假設是在80%中段。我想這三個資產大概更接近90%的區間。但考量生命科學空間的租約規模,較可能的情境是:不是100%滿租,就是低於75%的某個水準。它們通常是大面積、較「塊狀」的租約,但我們在近期做的多數收購案中,都已納入相當可觀的空置假設。Kelvin?

  • Kelvin Moses - Chief Financial Officer

    Kelvin Moses - Chief Financial Officer

  • Yeah. And then Austin, maybe on just the performance so far this year and how that might translate next year. We've done a pretty phenomenal job throughout the year. We had the opportunity to increase guidance due to the operating results of each of our businesses. So that's outpatient lab and senior housing that are outperforming our initial expectations.

    是的。然後 Austin,或許就今年迄今的表現,以及這可能如何反映到明年來談。我們今年整體做得相當出色。由於各業務的營運成果,我們有機會上調財測指引。也就是門診檢驗實驗室與高齡住宅的表現都優於我們最初的預期。

  • We continue to get the benefit from Janus Living from its organic growth and external growth. So that's a contributor to Healthpeak going into 2027. And naturally, as you know well, we're managing the balance sheet prudently. We have $1.4 billion maturing next year on balance sheet.

    我們持續受惠於 Janus Living 的內生成長與外部成長。因此,這將成為 Healthpeak 邁向 2027 年的一項貢獻來源。當然,如你很清楚的,我們正審慎管理資產負債表。我們資產負債表上明年到期的金額為 14 億美元。

  • We've taken some proactive measures to position ourselves well and have maximum flexibility to address those. But quite a bit of work to do on the balance sheet front going into 2027. So I want to make sure we highlight that. Given that our cost of borrowing that's maturing is around 3%, and that's certainly much lower than where the market is today.

    我們已採取一些前瞻性的措施,讓自己處於良好位置並保有最大的彈性來因應這些到期項目。但在邁向 2027 年之際,資產負債表方面仍有相當多工作要做。所以我想確保我們強調這一點。考量到我們即將到期的借款成本約在 3% 左右,而這顯然遠低於目前市場水準。

  • Scott Brinker - President, Chief Executive Officer, Director

    Scott Brinker - President, Chief Executive Officer, Director

  • [Okay], next question.

    [好的],下一個問題。

  • Operator

    Operator

  • Jim Kammert, Evercore ISI.

    Jim Kammert,Evercore ISI。

  • Jim Kammert - Analyst

    Jim Kammert - Analyst

  • Hi, good morning. Thank you. Again, back on the lab leasing and your constructive comments, can you quantify, are these tenants new to market on average in the transactions you're engaged on, leases done and discussions underway? Or are they bigger than neighbor from neighboring assets? I'm just curious what the overall tone for the market is, please?

    嗨,早安。謝謝。再回到實驗室租賃以及你們偏正向的評論,能否量化一下:在你們正在進行的交易(已簽租約與正在洽談中的)裡,這些承租方平均而言是市場新進者嗎?還是來自鄰近資產的較大型既有租戶?我只是想請教整體市場氛圍如何?

  • Kelvin Moses - Chief Financial Officer

    Kelvin Moses - Chief Financial Officer

  • I can give a little bit of context, Jim. From both an execution standpoint and the pipeline, I'd say 50% of our executions in active discussions are with existing clients, 50% with new clients. So the demand is developing from within our portfolio and it's coming from the marketplace.

    Jim,我可以補充一些背景。就執行面與案源管線來看,我會說我們目前正在積極洽談的成交案中,約 50% 來自既有客戶、50% 來自新客戶。因此,需求一方面從我們的資產組合內部發展出來,也同時來自外部市場。

  • As Scott mentioned earlier, you're getting the benefit of just continued improvement in biotechnology demand, but also the spillover technology adjacent demand that is attracted to our buildings that are highly flexible, that can accommodate those uses.

    如 Scott 先前提到的,你們正受惠於生物科技需求的持續改善,同時也受惠於與科技相鄰(technology-adjacent)的外溢需求;這些需求被我們高度彈性、可支援相關用途的建築所吸引。

  • So the demand is a certainly widespread geographically across each of our markets. It's probably proportional, I would say, to our footprint in those markets. We see a bit of activity in the Bay Area just given our scale.

    因此,需求在地理上確實相當分散,涵蓋我們各個市場。我會說大致上與我們在各市場的布局規模成正比。由於我們在灣區的規模,我們也看到那裡有一些活動。

  • But San Diego has been quite interesting. As you look at the way in which we've been able to lease in Torrey Pines and the demand that's coming in behind that, that's now eyeing and circling around our Western [on] Mesa portfolio. So a lot of positive indications in that pipeline that we've been seeing. And now the team is hard at work trying to convert that into LOIs and execution.

    但聖地牙哥相當有意思。當你看到我們在 Torrey Pines 的出租表現,以及其後續湧入的需求,現在也開始關注並圍繞我們位於 Western [on] Mesa 的資產組合。因此,我們在管線中看到許多正向訊號。而現在團隊正全力以赴,嘗試把這些轉化為意向書(LOI)並落實簽約。

  • Operator

    Operator

  • Rich Anderson, Cantor Fitzgerald.

    Rich Anderson,Cantor Fitzgerald。

  • Richard Anderson - Analyst

    Richard Anderson - Analyst

  • Started to keep this going. But I did -- I wanted to follow up with what you said -- something you said earlier, Scott, about same store, and you're not focusing on same-store and because it's a fungible calculation depending on what's going on at the present any moment.

    我先延續這個話題。不過我確實想追問你先前說的一點——Scott,你先前提到同店(same store),你們並不聚焦同店,因為在任何當下情況不同時,它是一個可替換、可變動的計算方式。

  • How would you describe the process of taking assets out of the pool and into the pool and redevelopment held for sale, all those forces at work, how does that impact your -- even though you're not focusing on same store, how does your focus [on] your same-store pool, particularly in medical office? What would be your comment around those observations? Thanks.

    你會如何描述把資產移出同店池、再移入同店池,以及重建(redevelopment)、待售(held for sale)等各種因素同時作用時的流程?即便你們不聚焦同店,這些因素如何影響你們——尤其在醫療辦公(medical office)方面——對同店資產池的關注?你對這些觀察有何評論?謝謝。

  • Scott Brinker - President, Chief Executive Officer, Director

    Scott Brinker - President, Chief Executive Officer, Director

  • Yeah, I mean we have 500-plus buildings in the outpatient space. I think we have five buildings on your redevelopment and we have nothing in held for sale. So there -- I don't know what percentage of that 9%. I don't know it's really high.

    是的,我們在門診領域有 500 多棟建築。我想我們大概有五棟在重建中,且沒有任何資產列為待售。所以——我不知道那占 9% 的多少比例。我不覺得比例真的很高。

  • Is not in redevelopment or held for sale. If the building needs to be redeveloped, it does happen. It's more likely in lab where you've got a full building that's been used for 20 years and you just have to start over from the base building all the way through the TIs, and that's a process that is a lot of money, and it makes sense to put a building like that in redevelopment.

    並沒有在重建或待售。如果某棟建築需要重建,確實會發生。這在實驗室資產更常見,因為你可能有一整棟建築已使用 20 年,必須從基礎建築一路到租戶裝修(TIs)全部重新來過;這是一個非常花錢的流程,因此把這樣的建築列入重建是合理的。

  • On multi-tenant net of office building, like it's more rare. On occasion, we do spend a fair amount of money. We've got a handful of them. We've had great success leasing them up. But I've always felt like this whole concept of moving stuff in and out of the pool is just very misleading. I understand why same store became a metric that the real estate community monitored, but I just think it's been abused.

    至於多租戶的淨租金(net)辦公類建築,這種情況就更少見。偶爾我們確實會投入相當多資本支出。我們手上有少數幾個。而我們在把它們出租滿方面非常成功。但我一直覺得,把資產在池子裡移進移出這整個概念其實非常誤導。我理解為什麼同店成為房地產圈會追蹤的指標,但我認為它已被濫用。

  • So I've had a very strong desire to move the culture of Healthpeak to being a health care real estate company and making the best real estate decisions to drive bottom line cash flow and away from more of a finance accounting mindset of moving things from one bucket to the next.

    因此,我一直很強烈地希望把 Healthpeak 的文化轉向:成為一家醫療照護不動產公司,做出最佳的不動產決策以推動底線現金流,而不是以更偏財務會計的思維,把東西從一個桶子移到下一個桶子。

  • And CapEx is another example of that. You can make the releasing spread wherever you want, just give the tenant a massive amount of same store of TI, and it bumps up the retention in the same store. And if it all impacts the top line, but not the bottom line.

    資本支出(CapEx)就是另一個例子。你想把續租價差(releasing spread)做成什麼樣都可以——只要給租戶非常大量的同店租戶裝修(TI),就能把同店的續租率墊高。而這些都會影響營收端(top line),但不會改善底線(bottom line)。

  • And we're only focused on the bottom-line cash flow. And that's how we run the business, and I think it's a disservice to the whole sector that people are so focused on same store. But we'll provide it because the sector requires it, but we don't run our company that way. Next question.

    而我們只專注於底線現金流。這就是我們經營公司的方式;我認為整個產業過度聚焦同店,對整個板塊是不利的。但我們仍會提供該數據,因為產業需要它;只是我們不以那種方式經營公司。下一個問題。

  • Operator

    Operator

  • Jamie Feldman, Wells Fargo.

    Jamie Feldman,Wells Fargo。

  • Jamie Feldman - Analyst

    Jamie Feldman - Analyst

  • Great. Thank you. I was hoping to dig a little deeper into the comments you made on debt maturities. So can you just give us a little bit more of your thoughts on debt coming due, what your options are, what you think the earnings drag might be to refi at the higher rates? And then I guess taking a step back.

    很好。謝謝。我想更深入了解你們對債務到期的評論。所以能否再多分享一些你們對即將到期債務的看法、你們有哪些選項,以及在較高利率下再融資(refi)可能對盈餘造成多大的拖累?然後我想再退一步。

  • Just capital needs in general, you've done a lot of leasing. It sounds like you'll have a decent amount of CapEx to get to that NOI in 12 to 15 months. Just how do we think about the puts and takes on your capital needs over the next year, so in line with and then your leverage targets as well and how you think those that plus of all fits together?

    就資本需求整體而言,你們做了很多出租。聽起來為了在 12 到 15 個月內達到那個 NOI,你們會需要相當程度的資本支出(CapEx)。那我們該如何看待未來一年你們資本需求的增減因素(puts and takes),以及你們的槓桿目標;你們如何看待這些因素如何相互配合?

  • Kelvin Moses - Chief Financial Officer

    Kelvin Moses - Chief Financial Officer

  • All right. I'll try to unpack the questions there. But maybe holistically, to start. We ended the quarter with 4.7 times net debt to EBITDA, which is a very strong balance sheet to begin with. And we certainly have some maturities coming in 2027 that we mentioned, about $1.4 billion that we're working towards.

    好的。我試著把這些問題拆開來回答。不過先從整體面來看。我們在本季末的淨負債對 EBITDA 倍數為 4.7 倍,這本身就是非常強健的資產負債表。而我們確實在 2027 年有一些到期項目,如我們提到的,約 14 億美元,我們正朝著處理這些到期項目努力。

  • We've made some proactive early decisions to position ourselves with $900 million of delayed draw term loan that we can access over the next two quarters. The first will be drawn in December and the second at some point in the first quarter of next year, which will help us reduce our CP balances and then work towards the maturities that are really coming forward in the first quarter. We have about $1.1 billion maturing in Q1.

    我們已經做出一些前瞻性的早期決策,透過一筆9億美元的延遲提用定期貸款(delayed draw term loan)來為自己做好布局,我們可在接下來兩個季度動用。第一筆將於12月提用,第二筆將在明年第一季的某個時間點提用,這將有助於我們降低商業本票(CP)餘額,並著手因應真正集中在第一季到期的債務。我們在第一季約有11億美元到期。

  • And from a strategy standpoint, I would say, we're obviously focused on the most cost-effective tools available to us that makes sense for our business at the time to be able to think about the long-term debt that we are comfortable with on balance sheet.

    從策略角度來看,我會說,我們顯然專注於在當下對我們業務而言合理、且可用的最具成本效益工具,以便思考我們在資產負債表上長期債務的舒適水位。

  • So too early to give you exactly what those tools will be that we're utilizing, but the bank debt market has been supportive and that is certainly the first step. And then we'll be able to utilize CP on an interim basis as we work through the decision-making around the balance sheet and long-term financing needs there. So quite a bit of flexibility that our team has put us in a position to have as we work towards those maturities.

    因此現在還太早,無法確切告訴你我們將使用哪些工具,但銀行債務市場一直相當支持,這無疑是第一步。接著,在我們就資產負債表與長期融資需求進行決策的過程中,我們也能在過渡期間使用商業本票(CP)。因此,隨著我們朝這些到期日邁進,團隊已讓我們具備相當大的彈性。

  • And then from a capital standpoint, I would say you should expect CapEx consistent with years past. We brought capital down considerably from 2025 to 2026 with the leasing that does come with TIs. So there will be some capital invested back into the buildings as we secure the occupancy, but don't have an expectation for CapEx dramatically in excess of where we are today.

    另外,從資本配置角度來看,我會說你應該預期資本支出(CapEx)與過往年度一致。由於租賃中包含租戶裝修(TIs),我們已將2025到2026年的資本支出大幅下調。因此,當我們確保入住率時,仍會有部分資本回投到建築物上,但不應預期資本支出會大幅高於我們目前的水準。

  • Operator

    Operator

  • Omotayo Okusanya, Deutsche Bank.

    Omotayo Okusanya,德意志銀行。

  • Omotayo Okusanya - Analyst

    Omotayo Okusanya - Analyst

  • Yes. Good morning, everyone, and congrats on the solid quarter and outlook. Again, realize you're not giving '27 guidance yet. But again, just thinking when we take a look at consensus numbers, consensus is not really implying any real earnings growth in '27 versus your updated '26 guidance?

    是的。各位早安,恭喜本季表現穩健且展望良好。再次說明,我知道你們尚未提供2027年的指引。不過,當我們看市場一致預期數字時,一致預期似乎並未反映2027年相較於你們更新後的2026年指引會有任何實質的獲利成長?

  • We've talked about some of the drag from interest expense. But again, we've also talked about really strong operating results heading into '27. So I'm just curious a little bit when you think about that? Where some of the puts and takes could be to end up with you guys starting to generate earnings acceleration, which has always been a goal after the past few years of not a lot of earnings growth?

    我們談過利息費用帶來的一些拖累。但同時,我們也談到在邁向2027年時營運成果其實非常強勁。所以我有點好奇你們怎麼看這件事?有哪些可能的正負因素(puts and takes),能讓你們開始產生獲利加速?畢竟在過去幾年獲利成長不多之後,這一直是個目標。

  • Scott Brinker - President, Chief Executive Officer, Director

    Scott Brinker - President, Chief Executive Officer, Director

  • It was pretty severe downturn in life science, it was 2,500 basis points of occupancy. I mean, I think some companies in that sector earnings are down 50% in four years. I mean we're essentially flat. I think we've done a remarkable job in light of what happened in life science, which was more than 50% of our business four years ago.

    生命科學領域的下行相當嚴重,入住率下滑了2,500個基點。我的意思是,該產業有些公司的獲利在四年內下滑了50%。而我們基本上是持平。考量到生命科學在四年前占我們業務超過50%,我認為我們在那樣的情況下做得非常出色。

  • So I think we've done a pretty remarkable job to keep earnings where they're at. Obviously, interest rates have changed pretty dramatically. That is a headwind. There's a lot of volatility. So hard to predict, but it's certainly a higher refinancing costs than we have in place, but Kelvin and the team are doing a great job to position us for as much flexibility with as many options as possible.

    所以我認為我們在維持目前獲利水準方面做得相當出色。顯然,利率已經出現相當劇烈的變化。這是一項逆風。市場波動很大。因此很難預測,但再融資成本確實高於我們目前的水準;不過Kelvin和團隊在為我們爭取最大彈性、保留盡可能多的選項方面做得非常好。

  • But this life sciences, it does take time. I mean we were still losing occupancy in 2025. And there's just a reality in real estate, the great pipeline that turns into executions that turns into commencements that turns into cash paid rent. I mean, that's a process, and it takes time. because of the build-out in particular, Kelvin mentioned earlier, plus or minus 12-month build-out for a lot of these spaces.

    但生命科學這塊確實需要時間。我的意思是,我們在2025年仍在流失入住率。而房地產有個現實:再好的租賃管線要轉成簽約、再轉成起租、再轉成收到現金租金。這是一個流程,而且需要時間。尤其因為裝修工程(build-out),如Kelvin先前提到,許多空間的裝修期大約正負12個月。

  • So it just takes time for those lease executions to turn into rent. And obviously, there's a capital cost in the interim. So I think all of that is playing into the timing of earnings growth. But I'll just note that we've increased guidance 3 times year-to-date and by $0.05 in total.

    所以這些租約簽署要轉化為租金收入確實需要時間。而且在此期間顯然會有資本成本。因此我認為這些因素都影響了獲利成長的時間點。但我也要指出,我們今年迄今已三度上調指引,合計上調0.05美元。

  • So I think we're making the most of the environment that we're in, and the team is doing a great job and really happy with the momentum across all three of our businesses. Okay, operator, just more.

    所以我認為我們正在充分把握所處的環境,團隊做得非常好,我也對我們三大業務的動能感到非常滿意。好的,接線員,再來一位。

  • Operator

    Operator

  • Juan Sanabria, BMO Capital Markets.

    Juan Sanabria,BMO資本市場。

  • Juan Sanabria - Analyst

    Juan Sanabria - Analyst

  • Hi. I think at the top of the call, you talked about MOB core growth accelerating. So hoping you could maybe frame that and the drivers of that pickup or acceleration for outpatient?

    嗨。我想在電話會議一開始,你提到MOB核心成長正在加速。所以希望你能說明一下,門診(outpatient)這一塊成長回升或加速的情況與驅動因素?

  • Scott Brinker - President, Chief Executive Officer, Director

    Scott Brinker - President, Chief Executive Officer, Director

  • Yeah, we had quite a few big lease expirations in '25 and '26 that we knew about that had a temporary impact on our growth rate in that business, but we're still in the 2.5% to 3% range. For the outpatient business, we're still getting great releasing spreads with very modest TIs important to put those two things together.

    好的,我們在2025年和2026年有不少大型租約到期,這是我們事先就知道的,對該業務的成長率造成了暫時性的影響,但我們仍維持在2.5%到3%的區間。就門診業務而言,我們仍取得很好的續租租金價差(releasing spreads),同時租戶裝修(TIs)非常溫和,這兩點需要放在一起看。

  • And we've grown occupancy the last two quarters, set aside the impact of transactions like the recap, but Mark and the team have actually grown total occupancy, two straight quarters. Fourth quarter, maybe closer to flat, plus or minus, but we see a real chance to materially move total occupancy higher in 2027.

    而且我們在過去兩個季度提高了入住率,先不考慮像資本重整(recap)這類交易的影響,Mark和團隊確實已連續兩個季度提升整體入住率。第四季可能更接近持平、上下些微波動,但我們看到在2027年有很大機會把整體入住率實質推升。

  • We have fewer expirations and the leasing pipeline is terrific. So we feel really good about the trajectory of that business, both on the top line but also the bottom line. Okay. Any more questions, operator?

    我們的到期租約更少,而租賃管線非常強勁。因此我們對該業務的走勢感到非常樂觀,不僅是營收端(top line),也包括獲利端(bottom line)。好的。接線員,還有其他問題嗎?

  • Operator

    Operator

  • That was the last question, and the conference is now concluded. Thank you for attending today's presentation. You --

    這是最後一個問題,本次電話會議到此結束。感謝各位參加今天的簡報。你們——